BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Baxter
Moodys
Mallinckrodt
McKesson
Fish and Richardson
Novartis
Deloitte
Boehringer Ingelheim
US Army

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,922,338

« Back to Dashboard

Which drugs does patent 5,922,338 protect, and when does it expire?

Patent 5,922,338 protects SANDOSTATIN LAR and is included in one NDA.

Protection for SANDOSTATIN LAR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-seven patent family members in twenty-five countries.
Summary for Patent: 5,922,338
Title: Polyol esters, their preparation and use in depot forms of pharmacologically active agents
Abstract:This invention provides a polyester of a polyol, said polyol containing at least 3 hydroxyl groups and having a molecular weight of up to 20,000 at least 1 hydroxyl group in said polyol being in the form of an ester, with a poly- or co-poly-lactic acid residue, each having a molecular weight of at least from 5,000. These are useful for parenteral depot formulations.
Inventor(s): Brich; Zdenek (Binningen, CH), Kissel; Thomas (Ehrenkirchen, DE)
Assignee: Novartis AG (Basel, CH)
Application Number:08/471,304
Patent Claim Types:
see list of patent claims
Formulation; Device; Dosage form;

Drugs Protected by US Patent 5,922,338

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis SANDOSTATIN LAR octreotide acetate INJECTABLE;INJECTION 021008-001 Nov 25, 1998 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novartis SANDOSTATIN LAR octreotide acetate INJECTABLE;INJECTION 021008-002 Nov 25, 1998 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novartis SANDOSTATIN LAR octreotide acetate INJECTABLE;INJECTION 021008-003 Nov 25, 1998 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,922,338

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Switzerland4671/83Aug 26, 1983

Non-Orange Book US Patents Family Members for Patent 5,922,338

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,922,682 Polyol esters, their preparation and use in depot forms of pharmacologically active agents ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 5,922,338

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 395584 ➤ Subscribe
Austria A271384 ➤ Subscribe
Australia 3234884 ➤ Subscribe
Australia 575066 ➤ Subscribe
Belgium 900406 ➤ Subscribe
Switzerland 656884 ➤ Subscribe
Cyprus 1556 ➤ Subscribe
Germany 3430852 ➤ Subscribe
Denmark 173556 ➤ Subscribe
Denmark 407284 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Healthtrust
AstraZeneca
Chinese Patent Office
Teva
Johnson and Johnson
QuintilesIMS
UBS
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot